[Tamoxifen and endometrial pathology]
- PMID: 21500468
[Tamoxifen and endometrial pathology]
Abstract
Tamoxifen is a non-steroid antiestrogen, used as adjuvant therapy for breast carcinoma in women with positive estrogen receptor (ER+). In this report we evaluated endometrial histological changes in women treated with Tamoxifen for ER+ breast carcinoma.
Material and method: We performed transvaginal ultrasonography for the endometrial thickness and biopsy of endometrium on a group of 125 symptomatic women with Tamoxifen therapy for ER+ breast carcinoma. The endometrial specimens were histologically processed for histological diagnosis.
Results: Of all patients, 49.6% had endometrial pathology (women with functional hemorrhage), and 32% had atrophic endometrium. Endometrial pathology was represented by endometrial simple hyperplasia 17.6%, and endometrial complex hyperplasia 8.8%. Endometrial complex hyperplasia with atypia was found in 5.6%, endometrial polyps in 11.2%, endometrial carcinoma in 4.8% and müllerian mixt tumor in 1.6%.
Conclusions: Endometrial pathology was more likely to be diagnosed in gynecological symptomatic postmenopausal and premenopausal women with breast carcinoma treated with Tamoxifen. Therefore, it is necessary that these patients to be supervise, first, with transvaginal ultrasonography for endometrium, and after, with biopsy of endometrium. All patients on long-term Tamoxifen therapy should be annually screened by endometrial biopsy for endometrial pathology.
Similar articles
-
Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen.Yonsei Med J. 2020 Apr;61(4):317-322. doi: 10.3349/ymj.2020.61.4.317. Yonsei Med J. 2020. PMID: 32233174 Free PMC article. Review.
-
Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound.J Clin Oncol. 2000 Oct 15;18(20):3464-70. doi: 10.1200/JCO.2000.18.20.3464. J Clin Oncol. 2000. PMID: 11032586 Clinical Trial.
-
Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer.Gynecol Oncol. 2000 Aug;78(2):181-6. doi: 10.1006/gyno.2000.5859. Gynecol Oncol. 2000. PMID: 10926800
-
The endometrium in breast cancer patients on tamoxifen.Arch Gynecol Obstet. 2000 Apr;263(4):170-7. doi: 10.1007/s004040050276. Arch Gynecol Obstet. 2000. PMID: 10834325
-
Endometrial pathologies associated with postmenopausal tamoxifen treatment.Gynecol Oncol. 2004 Aug;94(2):256-66. doi: 10.1016/j.ygyno.2004.03.048. Gynecol Oncol. 2004. PMID: 15297160 Review.
Cited by
-
Common Multiple Primary Cancers Associated With Breast and Gynecologic Cancers and Their Risk Factors, Pathogenesis, Treatment and Prognosis: A Review.Front Oncol. 2022 Jun 8;12:840431. doi: 10.3389/fonc.2022.840431. eCollection 2022. Front Oncol. 2022. PMID: 35756608 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical